hotspot -WSS

hotspot

author：knowledge 2025-09-30 18:54:05 - browse：758

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 'The boss' wants server deleted: New allegations emerge in Trump indictment

Wikipedia

knowledge

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Oprah kicked off a national conversation on obesity. Let's have it

Washington mulls new rules to avert another Change Healthcare

Behind warning on Apellis’s eye drug lies a conflict of interest

'The boss' wants server deleted: New allegations emerge in Trump indictment

An outrageous hospital charge: I paid $710 for an hour of babysitting

explore

hotspot

hotspot

Supreme Court strikes down use of affirmative action

There's no autism epidemic. It's an autism diagnosis epidemic

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why the world’s most expensive drug might be worth the price

The cancer drug shortage isn’t new — and neither are the solutions

The mammogram wars are not over

How one medical school became remarkably diverse

Abortion pill case raises question: who can sue the FDA?

Medicare details structure of new drug price negotiation program

Ending health disparities requires full federal government, panel says

focus

Hospitals, health systems can help patients avoid medical debt

Public health communication lessons from Covid

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Eliminate the waiting period for sterilization covered by Medicaid

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Biden announces an advanced cancer research initiative

Wikipedia

knowledge

explore

entertainment